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FGFR3 and TP53 mutations are frequent in superficial
papillary and invasive disease urothelial cell carcinoma
respectively. This high frequency of FGFR3 and TP53
mutations, led us to compare these two genetic alteration
in 81 bladder cancer tumors of all stages and grades at ini-
tial diagnosis, to determine whether they correspond to
different disease pathways and could be used for molecu-
lar classification of these tumors. Moreover, the role and
the position of FGFR3 mutations in the current models of
bladder carcinogenesis need to be clarified. We used dena-
turing high-performance liquid chromatography and
sequencing to screen for FGFR3 and TP53 mutations in 81
newly diagnosed urothelial cell carcinomas. FGFR3 muta-
tions were associated with low-stage (P < 0.0001), low-
grade (P < 0.008) tumors, whereas TP53 mutations were
associated with high-stage (P < 0.003), high-grade (P <
0.02) tumors. Mutations in these two genes were almost
mutually exclusive. Our results suggest that FGFR3 and
TP53 mutations define separate pathways at initial diag-
nosis of urothelial cell carcinoma. On the other hand,
given the high frequency of FGFR3 mutations and the pos-
sible implication of this receptor in the development of
UCC, it was important to develop a simple, fast, and reli-
able method to identify these mutations in greater detail
as a potential tool for the diagnosis and follow-up of UCC
patients. Ten different FGFR3 mutations have been
described in UCC, but 4 of them (R248C, S249C, G372C,
and Y375C) account for 95% of cases. Therefore in this
study we developed an allele specific PCR (AS-PCR) for
the detection of these mutations in tumors and urine. For
the 95 tumors examined, AS-PCR had a specificity of 90%
and a sensitivity of 88%. The test correctly identifies
FGFR3 mutations in the 20 tumors and the corresponding
urine samples investigated. However, because our study
was carried out on primary tumors rather on recurrent
tumors, which are usually smaller, a prospective study of
the diagnostic value of this test for the detection of recur-
rences should be undertaken.
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